Here are the S-3 shelf registrations from Aclaris Therapeutics, Inc. (ACRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ACRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRS filings page.
Aclaris Therapeutics, Inc. has put in place an automatic shelf registration on Form S‑3 as a well‑known seasoned issuer, replacing its prior shelf. The base prospectus covers the potential offering and sale, from time to time, of an indeterminate amount of common stock, preferred stock, debt securities and warrants by the company and any selling securityholders.
The filing also includes a separate prospectus for an “at‑the‑market” equity program allowing Aclaris to issue and sell up to $150,000,000 of common stock through Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents under a sales agreement dated August 6, 2026. Net proceeds, if any, are intended primarily for research and development of its immuno‑inflammatory product candidates, working capital and general corporate purposes, with potential use for complementary acquisitions.
Aclaris is a clinical‑stage biopharmaceutical company focused on novel small and large molecule candidates for immuno‑inflammatory diseases, leveraging its KINect discovery platform. It is classified as a smaller reporting company, which allows reduced disclosure requirements under SEC rules.